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cEditor, Indian Heart JournalThe American College of Cardiology (ACC) and American Heart
Association (AHA), incollaborationwiththeNationalHeart, Lung
and Blood Institute (NHLBI), have recently released a set of four
important guideline documents that provide recommendations
for blood cholesterol management in adults, management of
overweight and obesity, life-style modifications to reduce car-
diovascular (CV) risk and the approach to CV risk strat-
ification.1e4Ofthese, thecholesterolguidelineswereperhapsthe
most awaited, given the significant improvements that have
taken place in our understanding of lipidmanagement over the
past decade, since the previous NHLBI guidelines (adult treat-
ment panel III) were last updated.5 However, the new recom-
mendations depart heavily from the prevailing concepts in lipid
management and in this process have sparked off an intense
debate about their rationaleandpracticality. Therefore, a critical
review of these guidelines, along with the related document on
CV risk stratification, iswarranted beforewe embark on the task
to incorporate them in to our clinical practice.1. What is new in the new cholesterol
guidelines?
In 2008, the NHLBI expert panel set out to review the existing
literature on relationship between blood cholesterol levels and
CVdisease (CVD) and impact of various lipid lowering therapies
on CV risk. In order to be the most evidence-based, the NHLBI
advisory council required the expert committee to strictly* Corresponding author.
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http://dx.doi.org/10.1016/j.ihj.2014.01.003adhere to the highest quality data derived predominantly from
randomized controlled trials (RCTs), systematic reviews and
meta-analyses of RCTs. Thus, most of the recommendations
provided in the current guideline document are based on such
data only and, except in few circumstances, no recommenda-
tion has beenmade if a relevant RCT or meta-analysis was not
available to answer a particular critical question.1
In the pursuit to adhere to data derived mainly from RCTs,
the current guidelines have provided recommendations that
significantly depart from the existing practice. Unlike the
previous ATP III guidelines5 and all the current guidelines
from competent authorities (such as European Society of
Cardiology,6 American Diabetes Association7), the present
guidelines have completely set aside the need to define any
LDL-C thresholds or goals. Instead, four risk groups have been
identified that need to be prescribed either moderate or high-
intensity statin therapy, regardless of their baseline LDL-C
levels and without aiming for a particular pre-defined LDL-C
target. These risk groups include e 1) patients with clinically
evident atherosclerotic cardiovascular disease (ASCVD), 2)
those with primary elevations of LDL-C > 190 mg/dl, 3) di-
abetics aged 40e75 years and having LDL-C between 70 and
189 mg/dl, and 4) for everyone who is 40e79 years old, has
LDL-C above 70 mg/dl and in whom estimated 10-year risk of
hard CV disease is >7.5% (and even those with 5.0e7.5% risk)
according to the new risk algorithm. At the same time, the
guidelines have also identified patients for whom available
data do not support statin therapy and for whom noy of India. All rights reserved.
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ease patients requiring maintenance hemodialysis and those
with symptomatic heart failure. Finally, the panel also cited
the lack of RCT evidence to support the use of non-statin
cholesterol lowering drugs, either in combination with sta-
tins or as mono-therapy in statin-intolerant patients.12. What are the practical issues with these
recommendations?
The major strength of these guidelines is that they are based
on RCT data and also promise to simplify lipid management
by eliminating any need to focus on LDL-C targets and by
simplifying available therapeutic options for lipid lowering.
However, there are several practical challenges with this
approach as outlined below.
The elimination of LDL-C goals aims to prevent under-
treatment of individuals with LDL-C levels close to the ‘goals’
and unwarranted over-treatment of those with very high
baseline LDL-C levels who have achieved a significant fall in
LDL-C but LDL-C still remains above the ‘target’ level. However,
the reverse is also true. According to the new guidelines, a pa-
tient with significantly elevated LDL-C (e.g. 180 mg/dl) but
without other CV risk factors will not be a candidate for lipid
lowering therapy whereas another patient with marginally
elevated LDL-C (80 mg/dl) but without overt ASCVDwill qualify
for high-dose statin therapy, if overall 10-year risk of hard CV
events is>7.5%. These observations are clearly contradictory to
available trial data that show benefit with statin therapy in pa-
tients with high baseline LDL-C irrespective of other CV risk
factors.
Further, these recommendations are based on the premise
that in appropriately selected patients, high-intensity (defined
as the one resulting in50% reduction in LDL-C from baseline)
ormoderate-intensity (one that is expected to reduce LDL-C by
30e50%) statin therapyprovides themost favorable risk-benefit
ratio. However, it is well known that individual responses and
tolerability to statin therapy vary considerably, translating into
variable magnitude of LDL-C reduction with variable degree of
CV risk reduction. In the Cholesterol Treatment Trialists’ (CTT)
Collaborationmeta-analysis of 26 statin trials, itwas found that
each 1 mmol/l (w39 mg/dl) reduction in LDL-C was associated
with a 22% proportional reduction in major vascular events.8
Thus, the net benefit achieved correlated directly with the
magnitude of LDL-C reduction. Hence, a patient having sub-
optimal response to a particular statin dose is likely to benefit
from further intensification of life-style measures, an incre-
ment in the statin dose and/or change of statin preparation to
achieve adequate LDL-C reduction. However, in absence of a
pre-defined LDL-C goal, it will be difficult to determinewhether
a particular patient has achieved a desired fall in LDL-C or not.
In addition, successful achievement of LDL-C goal provides the
patient with a sense of accomplishment, boosts his/hermorale
and motivates him/her further to continue with the treatment
regimen. At the same time, persistently elevated LDL-C above
the goal canhelp improve patient compliance to the treatment,
esp by the adoption of a healthy life-style.
The notion that the current guidelines do not recommend
any LDL-C goal is actually not entirely correct. As mentionedabove, the present guidelines define high-intensity statin
therapy as the one that is expected to reduce LDL-C levels
by 50% and moderate-intensity statin therapy as the one
likely to reduce LDL-C by 30 to <50%. Therefore, if moderate-
intensity statin therapy is initiated in two patients with
baseline LDL-C of 150 mg/dl and 100 mg/dl respectively, their
LDL-C levels are expected to fall to approximately 80 mg/dl
and 50 mg/dl, respectively. Thus, the current guidelines do
also implicitly suggest what LDL-C level to expect in a patient
initiated on statin therapy but unlike the previous guidelines,
do not recommended any fixed LDL-C goals and do not
emphasize on rigidly following LDL-C levels. Nevertheless, for
the reasons mentioned above, it will be desirable to measure
LDL-C in patients on statin therapy but their interpretation
will now be problematic in many ways:
 The treating physician is now required to keep track of the
patient’s baseline LDL-C level during each follow-up visit to
be able to take decisions about the further course of lipid
lowering treatment.
 If a patient who is already on a statin visits a physician’s
clinic, the treating physician has to first find out his baseline
LDL-C level to determine whether his current LDL-C level is
acceptable ornot. For example, if a patient onmoderate dose
statin therapyhas LDL-C 90mg/dl, it doesnot tell uswhether
the statin dose needs to be increased or continued as such.
 It is not uncommon to find statin therapy being initiated
without obtaining baseline LDL-C levels. In such cases, it
will be difficult to make subsequent therapeutic decisions.
These issues are particularly relevant for Asian pop-
ulations in whom lower statin doses are very frequently used,
both because of poorer tolerability as well as more marked
LDL-C reduction as compared to western populations.9e11 In
such patients, adequacy of statin therapy cannot be deter-
mined without measuring on-treatment LDL-C.
Another controversial aspect of the new guidelines is the
complete denouncement of the role of non-statin drugs in the
management of dyslipidemia. Although it is true that there is
only limited RCT data to support use of non-statin drugs for
lipid lowering, some of these agents have shown promise. For
example, in the ACCORD Lipid study, when fenofibrate was
added to background statin therapy, it significantly reduced
the incidence of CV events in patients who had atherogenic
dyslipidemia.12 This is consistent with the data from older
studies comparing gemfibrozil and bezafibrate with placebo,
which showed significant CV risk reductionwith these agents,
with more marked effects seen in those with elevated tri-
glyceride levels.13e15 Furthermore, fibrates have been shown
to have additional non-cardiac benefits also, such as reduced
progression of diabetic retinopathy. These findings suggest
that fenofibrate may be a reasonable alternative in statin-
tolerant patients, particularly in diabetic subjects with
atherogenic dyslipidemia. Similarly, ezetimibe can be very
helpful in lowering LDL-C in patients who are not able to
achieve desired LDL-C reduction with maximally tolerated
statin dose. However, it is important to remember that no lipid
lowering drug can match statins in their efficacy to prevent
CVD and hence, use of non-statin drugs at the expense of
statins is not desirable and must be avoided.
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moderate intensity) for everyone who is 40e79 years old, has
LDL-C above 70 mg/dl and in whom estimated 10-year risk of
hard CV disease is >7.5% (and even those with 5.0e7.5% risk)
according to the new risk algorithm. This is a major deviation
from the existing recommendations that had proposed much
higher thresholds for initiation of statin therapy in primary
prevention setting in absence of diabetes.6,16 Data presented in
the accompanying CV risk assessment document shows that
>45% of the non-pregnant US population in the age group
40e79 years had an estimated 10-year risk of hard CV event
5.0%, translating into nearly 45 million middle-aged Ameri-
cans potentially being prescribed a statin.4,17 This is a huge
number, appears rather irrational and has already invited
sharp criticism from several quarters.3. Guidelines on approach to CV risk
assessment
The current guidelines for CV risk assessment have proposed
a new risk calculator which is based on data collected from
several large, racially and geographically diverse, modern
NHLBI-sponsored cohort studies, including the ARIC (Athero-
sclerosis Risk in Communities) study, Cardiovascular Health
Study and the CARDIA (Coronary Artery Risk Development in
Young Adults) study, combined with applicable data from the
Framingham Original and Offspring Study cohorts.4 The risk
score is based on same risk factors as in previous scorings
systems and includes smoking status, diabetes, systolic blood
pressure (along with treatment status) with total and high-
density lipoprotein cholesterol level, apart from age, gender
and race. The purpose of the new risk score is to provide risk
estimates which are more contemporary and therefore more
representative of the true CV risk status of the present popu-
lation. However, similar to the cholesterol guidelines, these
too have several contentious issues that need to be addressed:
1. An intense debate has already ensued about the accuracy of
the new risk calculator. Several leading researchers,
including Dr Paul Ridker from Brigham and Women’s Hos-
pital, USA, have suggested that the new risk calculator
overestimatesCVrisk.17Theyapplied thenewrisk algorithm
to patients included in three large-scale primary prevention
studies, namely Women’s Health Study,18 the Physicians’
Health Study,19 and the Women’s Health Initiative Obser-
vational Study20 and found that the new scoring system
overestimated risk by 75e150%.While thismay relate to the
fact that the patients included in these three studies were
healthier than the general US population, more data and
more analyses are required to provide the final answers.
2. The new risk algorithm cannot be applied to Asians as the
Asian populations were not adequately represented in the
studies used for developing this algorithm. It is already
known that because South-Asians tend to develop CV
disease at an earlier age than their western counterparts,
most of the commonly available risk assessment tools such
as Framingham risk score underestimate CV risk in South-
Asians.21,22 Strategies such as using a correction factor to
recalibrate CV risk in South-Asians have been proposed inthe past.23 In this context, the accuracy of new risk score in
Asians needs to be documented separately.
3. One of the major limitations of strategies aimed at primary
prevention of CVD has been the general indifference and
poor compliance of the common public towards preventive
measures. The problem is greatest in persons at intermedi-
ate risk, who, because of the absence of overt CV disease,
tend to under-recognize the risk of developing the disease in
future. A potential way to overcome this challenge is to
identify additional risk markers that can help further refine
CV risk so that those at ‘higher risk’ of developing CVD could
be specifically targeted. While numerous such risk markers
are being evaluated currently, the new guidelines have sug-
gested that only family history of premature CV disease,
coronary artery calcium (CAC) score, high-sensitive c-reac-
tive protein (hs-CRP) level and ankle-brachial index (ABI)
havesufficientdiscriminatoryvalue tobe included inroutine
clinical practice.4 Of these, family history of premature CVD
is a known major CV risk factor and is easy to obtain, the
other three tools have some or other practical limitation to
theirwide-spreaduse.CAC score, though sufficiently robust,
is expensive, not easily available and requires radiation
exposure which seriously limits its repeatability and there-
fore applicability for monitoring patients requiring primary
prevention ofCVD. Similarly, hs-CRPhas also been shown to
have a strong relationshipwith the risk of adverseCVevents
and is a target for statin therapyalso but is readily influenced
byany inflammatory condition compromising its specificity.
TheABI,whichmeasures the fall insystolic bloodpressure in
lower limbs, indirectly detects hemodynamically significant
occlusivediseaseof lower limbarteries.Thus, it is reallynota
tool for early detection of atherosclerosis and has limited
sensitivity in apparently asymptomatic patients undergoing
CV risk stratification. This is highlighted in the ABI collabo-
ration meta-analyses cited by the guideline document. In
spite of the significantly high mortality risk (20% over 10
years) in the studied population, only 7.7% had ABI <0.9.24
In contrast, carotid intima-media thickness is a simpler tool,
easily available, inexpensive and free from any side-effects.
Numerous large-scale studies have demonstrated its utility for
prediction of CV risk and most of the current guidelines,
including the previous AHA guideline on CV risk stratification,
endorse utility of CIMT in risk stratification of the patients
otherwise considered to be at ‘intermediate risk’.25,26Moreover,
by providing visual, structural evidence of atherosclerosis,
CIMT has also been shown to be useful in improving patient
compliance to treatment.27,28 Unfortunately, the current
guidelines have not recommended CIMT as a routine test citing
lack of outcomedata and also becauseof apprehensions related
to standardization ofmeasurement technique. Possibly, amore
rational approach would have been to emphasize upon its
standardization rather than to exclude it.4. Conclusions
“The absence of evidence to show benefit does not mean evidence
of absence of benefit”
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 1e44The recently published ACC/AHA guidelines for cholesterol
management and CV risk stratification have taken a bold step
by departing from the current clinical practice, in order to
adhere strictly to data derived from large-scale RCTs. At the
same time, these guidelines have also simplified lipid man-
agement approach by eliminating any need to define fixed
LDL-C goals and by simplifying therapeutic options. However,
in this process, these guidelines have raised several questions
that need to be answered before they could receive wide-
spread adoption in to regular clinical practice.r e f e r e n c e s
1. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: a report of the
American College of Cardiology/American Heart Association
Task Force on practice guidelines. Circulation. 2013.
2. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS
guideline for the management of overweight and obesity in
adults: a report of the American College of Cardiology/
American heart Association Task Force on practice guidelines
and the Obesity Society. Circulation. 2013.
3. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on
lifestyle management to reduce cardiovascular risk: a report
of the American College of Cardiology/American Heart
Association Task Force on practice guidelines. Circulation.
2013.
4. Goff Jr DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA
guideline on the assessment of cardiovascular risk: a report of
the American College of Cardiology/American Heart
Association Task Force on practice guidelines. Circulation. 2013.
5. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent
clinical trials for the National Cholesterol Education Program
adult treatment panel III guidelines. Circulation.
2004;110:227e239.
6. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines
for the management of dyslipidaemias: the Task Force for the
management of dyslipidaemias of the European Society of
Cardiology (ESC) and the European Atherosclerosis Society
(EAS). Eur Heart J. 2011;32:1769e1818.
7. Standards of medical care in diabetese2013. Diabetes Care.
2013;36:S11eS66.
8. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of
more intensive lowering of LDL cholesterol: a meta-analysis
of data from 170,000 participants in 26 randomised trials.
Lancet. 2010;376:1670e1681.
9. Matsuzawa Y, Kita T, Mabuchi H, et al. Sustained reduction of
serum cholesterol in low-dose 6-year simvastatin treatment
with minimum side effects in 51,321 Japanese
hypercholesterolemic patients. Circ J. 2003;67:287e294.
10. Wu CC, Sy R, Tanphaichitr V, Hin AT, Suyono S, Lee YT.
Comparing the efficacy and safety of atorvastatin and
simvastatin in Asians with elevated low-density lipoprotein-
cholesterolea multinational, multicenter, double-blind study.
J Formos Med Assoc. 2002;101:478e487.
11. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A. Comparison
of rosuvastatin versus atorvastatin in South-Asian patients at
risk of coronary heart disease (from the IRIS Trial). Am J
Cardiol. 2007;99:1538e1543.
12. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of
combination lipid therapy in type 2 diabetes mellitus. N Engl J
Med. 2010;362:1563e1574.13. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-
prevention trial with gemfibrozil in middle-aged men with
dyslipidemia. Safety of treatment, changes in risk factors,
and incidence of coronary heart disease. N Engl J Med.
1987;317:1237e1245.
14. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the
secondary prevention of coronary heart disease in men with
low levels of high-density lipoprotein cholesterol. Veterans
Affairs High-Density Lipoprotein Cholesterol Intervention
Trial Study Group. N Engl J Med. 1999;341:410e418.
15. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V,
Behar S. Bezafibrate for the secondary prevention of
myocardial infarction in patients with metabolic syndrome.
Arch Intern Med. 2005;165:1154e1160.
16. Third report of the National cholesterol Education Program
(NCEP) expert panel on detection, evaluation, and treatment
of high blood cholesterol in adults (Adult treatment panel III)
final report. Circulation. 2002;106:3143e3421.
17. Ridker PM, Cook NR. Statins: new American guidelines for
prevention of cardiovascular disease. Lancet.
2013;382:1762e1765.
18. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-
dose aspirin in the primary prevention of cardiovascular
disease in women. N Engl J Med. 2005;352:1293e1304.
19. Final report on the aspirin component of the ongoing
physicians’ health study. Steering committee of the
physicians’ health study Research group. N Engl J Med.
1989;321:129e135.
20. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL,
Trevisan M. The Women’s Health Initiative Observational
Study: baseline characteristics of participants and reliability
of baseline measures. Ann Epidemiol. 2003;13:S107e121.
21. Kanjilal S, Rao VS, Mukherjee M, et al. Application of
cardiovascular disease risk prediction models and the
relevance of novel biomarkers to risk stratification in Asian
Indians. Vasc Health Risk Manag. 2008;4:199e211.
22. Bansal M, Shrivastava S, Mehrotra R, Agarwal V, Kasliwal RR.
Low Framingham risk score despite high prevalence of
metabolic syndrome in asymptomatic North-Indian
population. J Assoc Physicians India. 2009;57:17e22.
23. Enas EA, Singh V, Munjal YP, et al. Recommendations of the
second Indo-U.S. health summit on prevention and control of
cardiovascular disease among Asian Indians. Indian Heart J.
2009;61:265e274.
24. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index
combined with Framingham Risk Score to predict
cardiovascular events and mortality: a meta-analysis. JAMA.
2008;300:197e208.
25. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound
to identify subclinical vascular disease and evaluate
cardiovascular disease risk: a consensus statement from the
American Society of Echocardiography carotid Intima-Media
thickness Task Force Endorsed by the Society for Vascular
Medicine. J Am Soc Echocardiogr. 2008;21:93e111.
26. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA
guideline for assessment of cardiovascular risk in
asymptomatic adults: a report of the American College of
Cardiology Foundation/American Heart Association Task
Force on practice guidelines. J Am Coll Cardiol.
2010;56:e50e103.
27. Bovet P, Perret F, Cornuz J, Quilindo J, Paccaud F. Improved
smoking cessation in smokers given ultrasound photographs
of their own atherosclerotic plaques. Prev Med.
2002;34:215e220.
28. Wyman RA, Gimelli G, McBride PE, Korcarz CE, Stein JH. Does
detection of carotid plaque affect physician behavior or
motivate patients? Am Heart J. 2007;154:1072e1077.
